Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NEO vs NDRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NEO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–3 Matrix Metrics)

NEO Overall Winner 6-Pillar Tally: NEO 4 – 2 NDRA Matrix Metrics: NEO 5 – 3 NDRA

As of Nov 17, 2026, NeoGenomics, Inc. (NEO) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NEO carries a Unified Composite Score of 35.6/100 (SELL) at $15.49 (N/M Forward P/E, -5.5% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. NEO 35.6/100 SELL), NEO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. 0.0% operating margin) and revenue trajectory (+11.4% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: NEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NEO vs NDRA
NEO NASDAQ Head-to-Head Winner
NeoGenomics, Inc.
Services-Testing Laboratories
$15.49
+0.55% 1D
Market Cap $2.1B
TTM Revenue $788M
Forward P/E N/M
Beta / 30D Vol 1.23β · 47% Vol
Unified Composite Score
35.6 / 100 SELL
Tech 23.0 Fund 44.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 38
RSI-14: 37.8 · SMA20: $16.85 · SMA50: $17.51
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32

6-Pillar Scorecard Institutional Category Breakdown (NEO 4 – 2 NDRA)

Columns: Metric · NEO · NDRA
1. Valuation Multiples NEO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 2.09x N/M
EV / Revenue 3.0x N/M
2. Growth & Scale NEO
Revenue Growth (YoY) +11.4% +0.0%
Earnings Growth (YoY) +130.6% +0.0%
TTM Revenue (USD) $788M N/A
Market Cap $2.1B $6.6M
3. Profitability & Quality NDRA
Gross Margin 44.8% N/A
Operating Margin -5.5% 0.0%
Net Profit Margin -4.1% 0.0%
Return on Equity (ROE) -3.9% -152.0%
4. Balance Sheet & Cash Flow NDRA
Cash Generation (TTM) -$29M -$8.0M
Cash Flow Margin -3.6% N/A
Net Cash / Leverage $310M Net Debt (0.56x D/E) $104,744 Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NEO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 100.0% (14th %ile) N/A (N/A)
Put/Call OI Skew 0.12x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat NEO
OpEx & R&D Intensity 50.3% of Rev ($396M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NEO (5) vs NDRA (3)
Institutional Metric NEO NDRA Criterion Row Edge
Market Capitalization
Scale
$2.1B $6.6M Larger Scale NEO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+11.4% +0.0% Higher Growth NEO
Operating Margin (TTM)
Profitability
-5.5% 0.0% Higher Margin NDRA
Net Profit Margin
Profitability
-4.1% 0.0% Higher Margin NDRA
Return on Equity (ROE)
Capital Efficiency
-3.9% -152.0% Higher ROE NEO
52-Week Range Position
Momentum
64% ($7–$20) 37% ($3–$7) Stronger Trend NEO
Beta / 30D Volatility
Risk Regime
1.23β · 47% Vol 0.71β · 48% Vol Lower Realized Risk NEO
Unified Institutional Score
Composite Signal
35.6 / 100 (SELL) 44.7 / 100 (HOLD) Higher Composite NDRA
Trailing 12M Revenue (USD)
Operating Scale
$788M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.09x PEG · 3.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$29M ($310M Net Debt (0.56x D/E)) -$8.0M ($104,744 Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NDRA +0.7 pp
NEO: -7.45% · NDRA: -6.75%
3M Horizon NDRA +1.08 pp
NEO: -3.08% · NDRA: -2.0%
6M Horizon NEO +102.41 pp
NEO: +84.11% · NDRA: -18.3%
1Y Horizon NEO +83.06 pp
NEO: +49.03% · NDRA: -34.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NEO Revenue NDRA Revenue NEO Op. Margin NDRA Op. Margin Margin Leader
FY2018 $280M $0M 3.6% -146080.5% NEO
FY2019 $410M N/A 3.2% N/A NEO
FY2020 $440M N/A -3.1% N/A NEO
FY2021 $480M N/A -24.5% N/A NEO
FY2022 $510M N/A -30.9% N/A NEO
FY2023 $590M N/A -18.2% N/A NEO
FY2024 $660M N/A -13.9% N/A NEO
FY2025 $730M N/A -15.9% N/A NEO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NEO CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 100.0%
IV Percentile 14th %ile
Put/Call OI Skew 0.12x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NEO Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.1B market capitalization and -5.5% operating margin.
OpEx & R&D Reinvestment 50.3% of Rev ($396M)
90D Engineering Disclosures 0 Published
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NEO vs NDRA Key Questions & Quantitative Answers

As of Nov 17, 2026, NeoGenomics, Inc. (NEO) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NEO carries a Unified Composite Score of 35.6/100 (SELL) at $15.49 (N/M Forward P/E, -5.5% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. NEO 35.6/100 SELL), NEO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. 0.0% operating margin) and revenue trajectory (+11.4% vs. +0.0% YoY). Technical & Structure Timing Caution: NEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NEO leads the Growth & Scale pillar: NEO posts +11.4% YoY revenue growth and +130.6% YoY earnings growth on $788M TTM revenue (44.8% gross margin, -5.5% operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NEO cumulative revenue shifted +160.7% while NDRA shifted N/A. In operating R&D and SG&A reinvestment, NEO deploys 50.3% of Rev ($396M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.

NEO screens cheaper on headline valuation multiples. NEO trades at N/M Forward P/E, N/M Trailing P/E, 2.09x PEG, and 3.0x EV/Revenue (-3.6% FCF margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEO (-3.9% ROE) versus NDRA (-152.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NEO carries 100.0% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.12x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.23β · 47% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.